The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.

Erinaldo Ubirajara Damasceno Dos SantosTiago F SampaioAléxia D Tenório Dos SantosFernanda C Bezerra LeiteRonaldo C da SilvaSergio CrovellaAmdore Guescel C AsanoNadja Maria Jorge AsanoPaulo Roberto E de Souza

Published in: The Journal of pharmacy and pharmacology (2018)

Clinical and demographic characteristics of Brazilian PD patients and differences in DRD2 and DAT1 genes may to determine individual variations in the therapeutic response to L-DOPA in the Brazilian PD patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
stem cells
parkinson disease
bone marrow
transcription factor
dna methylation
cell therapy
late onset